This current study discovered that DG treatment first increased the levels of taurine-conjugated BAs by suppressing the abundance of BSH related microbes in intestine of mice with obesity, which further resulted in restraint of ileal FXR-FGF15 axis to bring several obesity-related metabolic improvements like lower serum glucose and insulin levels, increased insulin sensitivity, few hepatic steatosis and resistance to weight gain. This evidence concerns the gene NR1H4 and Hepatic steatosis.